[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solitary-bone-plasmacytoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solitary-bone-plasmacytoma":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100601835",false,"NCT07115667","Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","Inclusion Criteria:\n\n* ≥18 years old\n* Histologically confirmed SBP with \\\u003C10% clonal plasma cells in marrow\n* ECOG ≤ 2\n* No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion.\n* Meets laboratory and imaging criteria\n\nExclusion Criteria:\n\n1. Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy.\n2. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","ALL","18 Years","78 Years",{"count":19,"type":20},21,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.",[26,27,28],"Solitary Bone Plasmacytoma","Plasmacytoma of Bone","Plasma Cell Disorders",[30,31],"solitary bone plasmacytoma","BCMA\u002FCD3 bispecific antibody","RECRUITING","2025-09-05",{"date":35,"type":36},"2025-09-08","ACTUAL",{"date":38,"type":36},"2025-08-25",{"date":40,"type":20},"2027-12-01",{"name":42,"class":43},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",""]